Form 4: WST CFO Robert McMahon Receives Equity Awards
Insider Transaction Report
West Pharmaceutical Services' CFO, Robert W. McMahon, was granted significant equity awards, including restricted stock units and stock options, on August 11, 2025.
Summary
- Robert W. McMahon, SVP & Chief Financial Officer of West Pharmaceutical Services Inc. (WST), was granted equity awards on August 11, 2025.
- Awards include 12,670 Restricted Stock Units (RSUs) vesting in three installments: 4,223 shares in 6 months, 6,335 shares in 12 months, and 2,112 shares in 24 months from the grant date.
- An additional 3,168 Restricted Stock Units (RSUs) were granted, vesting in four equal installments starting August 11, 2026.
- He also received 7,647 stock options and 7,137 stock options, both with an exercise price of $240.33. These options become exercisable in four equal installments beginning August 11, 2026, and expire on August 11, 2035.
Sentiment
Score: 7
Explanation: The filing indicates standard executive compensation, which is generally positive for aligning management incentives with shareholder interests, but does not contain new financial performance data.
Positives
- Grant of equity awards aligns management's interests with shareholders.
- The awards incentivize long-term performance and retention of a key executive.
Future Outlook
Not applicable. This filing is an insider transaction report and does not contain forward-looking statements or guidance.
Industry Context
Not applicable. This filing is specific to an individual's equity compensation and does not provide broader industry context.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorization of Agent | The filing includes a Limited Power of Attorney, authorizing specific individuals to execute and file SEC Forms 3, 4, and 5 on behalf of Robert W. McMahon. This is a standard compliance procedure. | 2025-08-04 | Enhances efficiency and compliance for SEC reporting by the executive. |
Stakeholder Impact
- Shareholders: Potential positive impact due to increased alignment of management's interests with shareholder value through equity ownership.
Next Steps
- Future vesting of Restricted Stock Units on specified dates.
- Future exercisability of Stock Options on specified dates.
Key Dates
| Date | Description |
|---|---|
| 2025-08-04 | Date Robert W. McMahon executed the Limited Power of Attorney for SEC filings. |
| 2025-08-11 | Date of earliest transaction (grant of equity awards). |
| 2025-08-12 | Date the Form 4 was signed by the agent. |
| 2026-02-11 | First vesting date for 4,223 shares of the 12,670 RSU award (6 months from grant). |
| 2026-08-11 | First vesting date for 6,335 shares of the 12,670 RSU award (12 months from grant) and first vesting date for the 3,168 RSU award (four equal installments beginning this date). Also, the date stock options become exercisable (four equal installments beginning this date). |
| 2027-08-11 | Vesting date for 2,112 shares of the 12,670 RSU award (24 months from grant). |
| 2035-08-11 | Expiration date for stock options. |
Recommendation
holdThis Form 4 filing details routine equity compensation for a senior executive, which is a standard practice to align management incentives with shareholder interests. It does not provide new financial performance data or strategic shifts that would warrant a change in investment recommendation. The grants are expected and do not signal a significant positive or negative catalyst for the stock price.
Keywords
West Pharmaceutical Services, WST, Robert W. McMahon, CFO, SEC Form 4, Restricted Stock Units, Stock Options, Equity Awards, Insider Transactions, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.